杜皮鲁玛
耐久性
医学
皮肤病科
材料科学
特应性皮炎
复合材料
作者
Claus Bachert,Asif Khan,Wytske J. Fokkens,Claire Hopkins,Philippe Gevaert,Joseph K. Han,Peter W. Hellings,Stella E. Lee,Jérôme Msihid,Scott D. Nash,Harry Sacks,Juby A. Jacob‐Nara,Yamo Deniz,Paul J. Rowe
标识
DOI:10.1016/j.jaci.2024.07.026
摘要
Most patients with CRSwNP achieve clinically meaningful responses to dupilumab by week 16, and most such patients in our study had maintenance and durability of response with continued treatment over time.
科研通智能强力驱动
Strongly Powered by AbleSci AI